Vedanta Biosciences, Inc.
Vedanta Biosciences is advancing first-in-class Live Biotherapeutic Products (LBP) to treat serious gastrointestinal diseases using defined consortia of bacteria. The company is committed to developing oral therapies based on human commensal bacteria to treat a wide range of debilitating diseases, with a focus on gastrointestinal conditions such as inflammatory bowel disease and Clostridium difficile infection. Led by a team of experts in immunology, microbiome research, and drug development, Vedanta aims to create new treatment options for patients through innovative microbiome-based medicines.
Industries
Nr. of Employees
medium (51-250)
Vedanta Biosciences, Inc.
Cambridge, Massachusetts, United States, North America
Patents
Products
Oral defined bacterial consortium for prevention of recurrent Clostridioides difficile infection (late-stage clinical program)
A standardized oral live bacterial therapy developed to reduce recurrence of C. difficile infection; evaluated in randomized, placebo-controlled late-stage clinical studies with a defined dosing course.
Oral defined bacterial consortium for treatment of ulcerative colitis (mid-stage clinical program)
A standardized oral live bacterial therapy under investigation for mild-to-moderate ulcerative colitis in randomized, placebo-controlled clinical trials.
Oral defined bacterial consortium for prevention of recurrent Clostridioides difficile infection (late-stage clinical program)
A standardized oral live bacterial therapy developed to reduce recurrence of C. difficile infection; evaluated in randomized, placebo-controlled late-stage clinical studies with a defined dosing course.
Oral defined bacterial consortium for treatment of ulcerative colitis (mid-stage clinical program)
A standardized oral live bacterial therapy under investigation for mild-to-moderate ulcerative colitis in randomized, placebo-controlled clinical trials.
Services
Scale-up production and manufacturing processes for standardized live microbial consortia intended for clinical use.
Design and operational execution of randomized Phase 2 and Phase 3 clinical studies evaluating oral live microbial therapies.
Scale-up production and manufacturing processes for standardized live microbial consortia intended for clinical use.
Design and operational execution of randomized Phase 2 and Phase 3 clinical studies evaluating oral live microbial therapies.
Expertise Areas
- Clinical trial management
- Live biotherapeutic development
- Microbiome therapeutics
- Biomanufacturing of live organisms
Key Technologies
- Live biotherapeutic products (LBPs)
- Defined bacterial consortia
- Oral microbial delivery
- Microbiome analysis and strain characterization
News & Updates
On 01/23/2025, Vedanta Biosciences announced the publication of additional Phase 2 VE303 results in Nature Medicine.
A publication detailing a clinical trial on VE303 for preventing recurrent C. difficile infection.
An article discussing the role of gut microbiome in fighting cancer and infection.
On 01/23/2025, Vedanta Biosciences announced the publication of additional Phase 2 VE303 results in Nature Medicine.
A publication detailing a clinical trial on VE303 for preventing recurrent C. difficile infection.
An article discussing the role of gut microbiome in fighting cancer and infection.